Weight regain with discontinuation of semaglutide for weight management

Data from a 68-week randomized trial of 902 patients with obesity (or overweight plus at least 1 weight-related condition) and without diabetes. All participants received subcutaneous semaglutide during the 20-week prerandomization run-in period. At week 20, participants who tolerated semaglutide 2.4 mg once weekly (n = 803) were randomized to continued semaglutide or placebo. Dotted vertical line indicates time of randomization.